Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - Day One Biopharmaceuticals is focused on developing new medicines for individuals with life-threatening diseases, emphasizing their commitment to making a significant impact in the healthcare sector [3]. Company Overview - Day One Biopharmaceuticals has treated over 1,000 children with its approved product, OJEMDA, showcasing the company's progress and dedication to its mission [3]. - The leadership team includes CEO Jeremy Bender, CCO Lauren Merendino, COO and CFO Charles York, and Head of R&D Mike Vasconcelles, indicating a strong management structure [2]. Industry Context - The presentation took place at the 44th Annual JPMorgan Healthcare Conference, highlighting the importance of investor engagement in the biopharmaceutical industry [1]. - The company aims to address the needs of patients across all ages, reflecting a broad commitment to healthcare innovation [3].